openPR Logo
Press release

Potential of Anti-influenza Drugs For The Control of High Pathogenicity Avian Influenza in Birds

Potential of Anti-influenza Drugs For The Control of High

Scientists have discovered a route of introduction for High Pathogenicity Avian Influenza Virus (HPAIV) H5N8 into Japan and, in parallel, have investigated the potential of two human anti-influenza drugs for the control of HPAI in birds.

Since October 30, 2020, there have been over 30 recorded outbreaks of High Pathogenicity Avian Influenza (HPAI) in domestic poultry and wild fowl in Japan. This outbreak was caused by the influenza A virus H5N8, a known High Pathogenicity Avian Influenza Virus (HPAIV). In such a scenario, identification of the source of the virus and its transmission route is important to control its spread.

A team of scientists led by Professor Yoshihiro Sakoda of Hokkaido University have recently found the probable route of introduction of the current HPAIV into Japan -- by migratory birds from Europe. Separately, they showed that anti-influenza drugs used for humans can potentially be used to treat HPAI in poultry and wild fowl, providing an alternative to culling infected birds. Their findings were published within a week of each other in the journal Viruses.

HPAI is a devastating disease in poultry, leading to large losses both economically and materially. Once present in domesticated poultry, the primary means of controlling HPAI is by culling all infected populations. There is no approved drug for the treatment of HPAI. In addition, it can infect captive wild birds, such as those in zoos and sanctuaries, which has major implications for the protection and conservation of endangered species.

In addition, HPAI is closely related to influenza in humans; certain strains of HPAIV have jumped to humans in the past, most recently in mid February 2021, in Russia. For prevention and control, it is vital to track the spread of this disease.

The scientists collected migratory duck feces samples from the lakeside of Lake Komuke, eastern Hokkaido in October 2020. After a number of tests, they confirmed the presence of H5N8 virus in one of the samples. Further, their genetic analysis showed that the H5N8 virus was closely related to the variants that caused outbreaks in Europe from late 2019 to early 2020 and the variants found in Korea and southern Japan from October to November 2020, rather than from the H5N8 viruses in East Asia from 2018-2019. This suggested that the H5N8 virus transmitted with migratory birds from Europe to Eastern Asia within 10 months. In addition, the team found that it is a different H5N8 variant that is causing current outbreaks in Europe, raising the alarm that the northern biosphere is becoming a reservoir of HPAIV.

The scientists also investigated two antivirals, baloxavir marboxil (BXM) and peramivir (PR), used for the treatment of influenza in humans for their potential to treat HPAI in poultry. In their experiments, both drugs improved the survival rate of infected chickens and reduced viral amounts in their organs and feces, with BXM showing higher efficacy. Further work on BXM suggested that an early single-administration of BXM at doses of 2.5 mg/kg or higher would be most effective for the treatment of HPAI in real-life settings.

"Based on our findings, the government authorities warned poultries in Japan in November last year, which helped local businesses take measures to prevent potential outbreaks. As in the past years, we will continue to monitor HPAIV in migratory birds visiting Hokkaido as well as researching possible treatments of the disease," said Sakoda.

The next steps would be to confirm if the strain of H5N8 detected by the scientists is responsible for the ongoing HPAI outbreak in Japan, and to verify if BXM is capable of treating HPAI in rare wild birds and poultry farms.

As a leading pharmaceutical intermediates supplier in China, Huateng Pharma provides the services of Anti-Viral intermediates’ process development and scale-up production with capacities varying from gram to kilograms and multi tons, such as oseltamivir intermediates, remdesivir intermediates, favipiravir impurities and baloxavir marboxil intermediates, etc.

Hunan Huateng Pharmaceutical Co. Ltd.
Lugu Business Plaza E1, Yuelu District, Changsha City, Hunan Province, P.R. China
zip code: 410205
Telephone: +86 731 89916275
Fax: +86 0731-82251112-818

Huateng Pharma is a leading supplier for a variety of pharmaceutical intermediates used in research and development. We can provide antidiabetic drugs intermediates such as liraglutide intermediates and semaglutide intermediates for your research. We can make scale-up production with capacities varying from gram to kilograms and multi tons.

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Potential of Anti-influenza Drugs For The Control of High Pathogenicity Avian Influenza in Birds here

News-ID: 2266242 • Views: 551

More Releases from Hunan Huateng Pharmaceutical Co. Ltd.

Huateng Pharma Develops Systemic Antiparasitic Agent Fluralaner
Fluralaner is a systemic insecticide and acaricide that can be administered orally or topically. Bravecto is the trade name. The U.S. Food and Drug Administration (FDA) approved it for flea treatment in dogs under the trade name Bravecto in May 2014 and for topical treatment in cats in November 2019. Fluralaner is a novel isooxazoline broad-spectrum insecticide that acts on γ-aminobutyric acid (GABA) receptors and has good activity against ticks, fleas,
Huateng Pharma Develops Intermediates of Carfilzomib For Multiple Myeloma
Carfilzomib, a proteasome inhibitor, is indicated for the treatment of patients with multiple myeloma. Multiple myeloma (multiple myeloma, MM) is a malignant tumor originating from the B cell lineage, characterized by the clonal proliferation of malignant plasma cells in the bone marrow microenvironment, causing fractures and bone marrow failure, and is the second most common blood system disease in the world Tumors cannot be cured by traditional chemotherapy regimens. Bortezomib is the
Huateng Pharma Develops Intermediates of Semaglutide For TD2
According to the latest IDF Diabetes map, the global prevalence of diabetes reached 10.5% in 2021, with 537 million adults living with diabetes. China has become a disaster zone for diabetes, with the largest number of adults with diabetes in the world. In the past 10 years (2011-2021), the number of people with diabetes in China increased from 90 million to 140 million, an increase of 56%. The total number
The Future of Treatment For Type 2 Diabetes
Although the treatment of type 2 diabetes (T2DM) has made impressive progress in the past few decades, researchers are constantly searching for new treatments. How to better control blood glucose and reduce diabetes-related complications has become a hot topic in the field of T2DM research. Previously, The Lancet Diabetes Endocrinology published an in-depth review detailing novel therapeutic targets for T2DM, mechanisms of drug action, and corresponding hypoglycemic efficacy. It involves innovation

All 5 Releases

More Releases for HPAI

South America Poultry Vaccines Market Is Likely to Experience a Tremendous Growt …
The SAM poultry vaccines market is expected to grow from US$ 183.82 million in 2021 to US$ 277.90 million by 2028; it is estimated to grow at a CAGR of 6.1% from 2021 to 2028. View Full Report with TOC @ “South America Poultry Vaccines Market” study by The Business Market Insights provides details about the market dynamics affecting the market, Market scope, Market segmentation and overlays shadow upon the
Poultry Vaccines Market Astonishing Growth with Top Influencing Key Players like …
Latest research on Poultry Vaccines Market report covers forecast and analysis on a worldwide, regional and country level. The study provides historical information of 2016-2021 together with a forecast from 2021 to 2026 supported by both volume and revenue (USD million). The entire study covers the key drivers and restraints for the Poultry Vaccines market. this report included a special section on the Impact of COVID19. Also, Poultry Vaccines Market
High Potency APIs (HPAPI) Market Share, Size 2020 Global Growth, New Updates, Tr …
To identify the scope of Global High Potency APIs (HPAPI) Market 2020, this report is prepared by in-depth analysis of historical data. The report forecasts the market size by the end of 2025 at an impressive CAGR provided by Market Research Reports. The report offers detailed outline of High Potency APIs (HPAPI) Market and vital market trends. The prime agenda of this report is to provide a detailed analysis of
High Potency API /HPAPI Market Research Report| Key Players - High Potency API / …
High Potency API /HPAPI use small molecules to supply new patient treatment of respiratory disorders, treatment of cancer and hormonal imbalances. These drugs have minimal side effects and impact targeted areas, thereby helping the patient to recover faster with no lingering after effects. FREE Sample report is instantly available at @ Global High Potency API /HPAPI Market research report identifies, assesses, and analyses the up-and-coming trends along with major
Comprehensive Study on Poultry Diagnostics Market 2018 Global Analysis by Top Ke …
Poultry Diagnostics Market Global Research Report 2018 provides comprehensive understandings of Sports Artificial Turf Market based on historical study and evaluates future projections for the period 2018-2025. Further, the report covers current market share, growth, trends and forecast with respect to market segments at country and regional level. The report also analyses the top companies in the Poultry Diagnostics industry. Poultry-derived food products signifies a substantial part of agricultural and food
Market Headed for Growth and Global Expansion by 2026
The global frozen processed food market was valued at US$ 60.12 billion in 2016 and is expected to reach US$ 85.49 billion by 2025, witnessing a CAGR of 4.01% over the forecast period (2017 - 2025), according to Frozen Processed Food Market Report, by Product Type (Frozen Bakery Products, Frozen Desserts, Frozen Processed Meat Substitutes, Frozen Processed Fish/Sea Food, Frozen Processed Poultry, Frozen Processed Meat, Frozen Processed Pizza, Frozen Processed Noodles, Frozen Processed